Treatment: combined hormonal contraception

Gynaecology and obstetrics · Treatment monitoring · updated 2026-10-30

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: In France, 2 370 205 women were using combined oral contraception in January 2022, i.e. 35% of contraception users (6.73 million, i.e. 46% of women aged 15 to 49), compared with 3 602 803 in 2012 (number of women, SNDS reimbursement data) ^[1].

Treatment: combined hormonal contraception

Fasting sample.

Fasting laboratory tests

Fasting plasma glucose
Lipid profile
β-hCG (if pregnancy is not excluded before starting)if neededThe SmPC requires that pregnancy be excluded before starting or restarting treatment ^[2].
Chlamydia trachomatis and Neisseria gonorrhoeae NAAT (PCR) (woman aged 15 to 25, or risk factor)if neededSexually active woman aged 15 to 25 years inclusive (routine opportunistic screening), or over 25 years with a risk factor: vaginal sample, possibly self-collected ^[3].

Detailed explanation and international comparison (in French): read it in English (machine translation)

Do not order

Routine thrombophilia screen before combined oestrogen-progestogen contraception, in the absence of a family history of vascular disease: not recommended ^[5].
Routine haemostasis tests: not necessary, except personal or family history of vascular disease ^[4].

Sources (9)